nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—ROS1—brain—conduct disorder	0.024	0.0456	CbGeAlD
Crizotinib—EPHA7—brain—conduct disorder	0.022	0.0417	CbGeAlD
Crizotinib—NEK9—brain—conduct disorder	0.0119	0.0227	CbGeAlD
Crizotinib—PRKD1—brain—conduct disorder	0.0109	0.0207	CbGeAlD
Crizotinib—SIK2—brain—conduct disorder	0.0107	0.0204	CbGeAlD
Crizotinib—LIMK1—brain—conduct disorder	0.0107	0.0204	CbGeAlD
Crizotinib—PRKD3—brain—conduct disorder	0.0105	0.0199	CbGeAlD
Crizotinib—DSTYK—brain—conduct disorder	0.0102	0.0194	CbGeAlD
Crizotinib—LTK—brain—conduct disorder	0.00998	0.0189	CbGeAlD
Crizotinib—CASK—brain—conduct disorder	0.00998	0.0189	CbGeAlD
Crizotinib—MAPK7—brain—conduct disorder	0.00967	0.0183	CbGeAlD
Crizotinib—EPHA8—brain—conduct disorder	0.00957	0.0182	CbGeAlD
Crizotinib—FES—brain—conduct disorder	0.00957	0.0182	CbGeAlD
Crizotinib—MET—brain—conduct disorder	0.00905	0.0172	CbGeAlD
Crizotinib—CDK7—brain—conduct disorder	0.00875	0.0166	CbGeAlD
Crizotinib—TAOK2—brain—conduct disorder	0.00869	0.0165	CbGeAlD
Crizotinib—ACVR1B—brain—conduct disorder	0.00837	0.0159	CbGeAlD
Crizotinib—EPHA3—brain—conduct disorder	0.00837	0.0159	CbGeAlD
Crizotinib—EPHA6—brain—conduct disorder	0.00798	0.0151	CbGeAlD
Crizotinib—JAK3—brain—conduct disorder	0.00798	0.0151	CbGeAlD
Crizotinib—DCLK1—brain—conduct disorder	0.00793	0.015	CbGeAlD
Crizotinib—PLK4—brain—conduct disorder	0.00788	0.015	CbGeAlD
Crizotinib—STK4—brain—conduct disorder	0.00783	0.0149	CbGeAlD
Crizotinib—TYRO3—brain—conduct disorder	0.0074	0.014	CbGeAlD
Crizotinib—FER—brain—conduct disorder	0.0074	0.014	CbGeAlD
Crizotinib—EPHA5—brain—conduct disorder	0.0074	0.014	CbGeAlD
Crizotinib—ALK—brain—conduct disorder	0.0074	0.014	CbGeAlD
Crizotinib—LYN—brain—conduct disorder	0.00737	0.014	CbGeAlD
Crizotinib—TNK1—brain—conduct disorder	0.00733	0.0139	CbGeAlD
Crizotinib—MAP4K1—brain—conduct disorder	0.00725	0.0138	CbGeAlD
Crizotinib—BMPR1B—brain—conduct disorder	0.00725	0.0138	CbGeAlD
Crizotinib—MAP3K19—brain—conduct disorder	0.00725	0.0138	CbGeAlD
Crizotinib—TNK2—brain—conduct disorder	0.00711	0.0135	CbGeAlD
Crizotinib—IGF1R—brain—conduct disorder	0.00711	0.0135	CbGeAlD
Crizotinib—MAP4K2—brain—conduct disorder	0.00701	0.0133	CbGeAlD
Crizotinib—STK3—brain—conduct disorder	0.00692	0.0131	CbGeAlD
Crizotinib—TIE1—brain—conduct disorder	0.00692	0.0131	CbGeAlD
Crizotinib—AURKA—brain—conduct disorder	0.00674	0.0128	CbGeAlD
Crizotinib—TESK1—brain—conduct disorder	0.00669	0.0127	CbGeAlD
Crizotinib—MERTK—brain—conduct disorder	0.00651	0.0123	CbGeAlD
Crizotinib—LIMK2—brain—conduct disorder	0.00636	0.0121	CbGeAlD
Crizotinib—NUAK2—brain—conduct disorder	0.00634	0.012	CbGeAlD
Crizotinib—MAP3K12—brain—conduct disorder	0.0063	0.0119	CbGeAlD
Crizotinib—ACVR1—brain—conduct disorder	0.0063	0.0119	CbGeAlD
Crizotinib—STK35—brain—conduct disorder	0.00617	0.0117	CbGeAlD
Crizotinib—ABL2—brain—conduct disorder	0.00601	0.0114	CbGeAlD
Crizotinib—BMP2K—brain—conduct disorder	0.00594	0.0113	CbGeAlD
Crizotinib—PTK2B—brain—conduct disorder	0.00573	0.0109	CbGeAlD
Crizotinib—RIPK2—brain—conduct disorder	0.00569	0.0108	CbGeAlD
Crizotinib—EPHA4—brain—conduct disorder	0.0055	0.0104	CbGeAlD
Crizotinib—MAP3K2—brain—conduct disorder	0.00539	0.0102	CbGeAlD
Crizotinib—PTK2—brain—conduct disorder	0.00528	0.01	CbGeAlD
Crizotinib—TBK1—brain—conduct disorder	0.00528	0.01	CbGeAlD
Crizotinib—TYK2—brain—conduct disorder	0.00524	0.00995	CbGeAlD
Crizotinib—IRAK1—brain—conduct disorder	0.00518	0.00982	CbGeAlD
Crizotinib—RPS6KB1—brain—conduct disorder	0.00508	0.00964	CbGeAlD
Crizotinib—FGR—brain—conduct disorder	0.00505	0.00958	CbGeAlD
Crizotinib—AXL—brain—conduct disorder	0.00503	0.00954	CbGeAlD
Crizotinib—SLK—brain—conduct disorder	0.00484	0.00918	CbGeAlD
Crizotinib—EPHB4—brain—conduct disorder	0.00481	0.00912	CbGeAlD
Crizotinib—JAK2—brain—conduct disorder	0.00477	0.00905	CbGeAlD
Crizotinib—EPHA2—brain—conduct disorder	0.00471	0.00894	CbGeAlD
Crizotinib—MAP3K3—brain—conduct disorder	0.0046	0.00872	CbGeAlD
Crizotinib—TEK—brain—conduct disorder	0.0046	0.00872	CbGeAlD
Crizotinib—MAP4K5—brain—conduct disorder	0.0046	0.00872	CbGeAlD
Crizotinib—EPHB6—brain—conduct disorder	0.0044	0.00834	CbGeAlD
Crizotinib—YES1—brain—conduct disorder	0.00425	0.00806	CbGeAlD
Crizotinib—STK10—brain—conduct disorder	0.00421	0.00798	CbGeAlD
Crizotinib—TAOK3—brain—conduct disorder	0.00419	0.00795	CbGeAlD
Crizotinib—SRC—brain—conduct disorder	0.00409	0.00775	CbGeAlD
Crizotinib—CSF1R—brain—conduct disorder	0.00367	0.00696	CbGeAlD
Crizotinib—ABL1—brain—conduct disorder	0.0029	0.0055	CbGeAlD
Crizotinib—ABCB1—brain—conduct disorder	0.000902	0.00171	CbGeAlD
Crizotinib—PRKD1—Metabolism—COMT—conduct disorder	0.000533	0.00113	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—WASF1—conduct disorder	0.000532	0.00113	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—WASF1—conduct disorder	0.00053	0.00112	CbGpPWpGaD
Crizotinib—PRKD1—Metabolism—MAOA—conduct disorder	0.000529	0.00112	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—CGA—conduct disorder	0.000526	0.00111	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—DRD4—conduct disorder	0.000524	0.00111	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—POLR3A—conduct disorder	0.000521	0.0011	CbGpPWpGaD
Crizotinib—BLK—Immune System—WASF1—conduct disorder	0.00052	0.0011	CbGpPWpGaD
Crizotinib—FGR—Immune System—WASF1—conduct disorder	0.000518	0.00109	CbGpPWpGaD
Crizotinib—ABL1—Cell Cycle—EP300—conduct disorder	0.000515	0.00109	CbGpPWpGaD
Crizotinib—PRKD1—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000513	0.00108	CbGpPWpGaD
Crizotinib—NTRK1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000512	0.00108	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—DRD4—conduct disorder	0.00051	0.00108	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—HTR2A—conduct disorder	0.000506	0.00107	CbGpPWpGaD
Crizotinib—LYN—Immune System—MB21D1—conduct disorder	0.000504	0.00107	CbGpPWpGaD
Crizotinib—PTK2—Immune System—POLR3A—conduct disorder	0.000503	0.00106	CbGpPWpGaD
Crizotinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.000503	0.00106	CbGpPWpGaD
Crizotinib—ABL1—Immune System—MB21D1—conduct disorder	0.000502	0.00106	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—WASF1—conduct disorder	0.000501	0.00106	CbGpPWpGaD
Crizotinib—MET—Developmental Biology—EP300—conduct disorder	0.000498	0.00105	CbGpPWpGaD
Crizotinib—YES1—Immune System—POLR3A—conduct disorder	0.000497	0.00105	CbGpPWpGaD
Crizotinib—TXK—Innate Immune System—EP300—conduct disorder	0.000493	0.00104	CbGpPWpGaD
Crizotinib—NTRK1—Circadian rythm related genes—EP300—conduct disorder	0.000491	0.00104	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—CGA—conduct disorder	0.000489	0.00103	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—DRD4—conduct disorder	0.000479	0.00101	CbGpPWpGaD
Crizotinib—JAK2—Immune System—MB21D1—conduct disorder	0.000472	0.000998	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—POLR3A—conduct disorder	0.000471	0.000996	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—DRD4—conduct disorder	0.000463	0.00098	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—POLR3A—conduct disorder	0.000461	0.000975	CbGpPWpGaD
Crizotinib—TYK2—Immune System—POLR3A—conduct disorder	0.000457	0.000967	CbGpPWpGaD
Crizotinib—CYP3A5—Biological oxidations—COMT—conduct disorder	0.000452	0.000955	CbGpPWpGaD
Crizotinib—CYP3A5—Biological oxidations—MAOA—conduct disorder	0.000448	0.000948	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways in Glioblastoma—EP300—conduct disorder	0.000447	0.000945	CbGpPWpGaD
Crizotinib—CYP3A5—Metapathway biotransformation—COMT—conduct disorder	0.000445	0.000942	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—CGA—conduct disorder	0.000439	0.000927	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—WASF1—conduct disorder	0.000439	0.000927	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CGA—conduct disorder	0.000436	0.000921	CbGpPWpGaD
Crizotinib—FES—Developmental Biology—EP300—conduct disorder	0.000435	0.00092	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—HTR2A—conduct disorder	0.00043	0.00091	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CGA—conduct disorder	0.000429	0.000908	CbGpPWpGaD
Crizotinib—PTK2—Immune System—WASF1—conduct disorder	0.000424	0.000896	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—DRD4—conduct disorder	0.000419	0.000885	CbGpPWpGaD
Crizotinib—SRC—Androgen receptor signaling pathway—EP300—conduct disorder	0.000418	0.000885	CbGpPWpGaD
Crizotinib—YES1—Immune System—WASF1—conduct disorder	0.000418	0.000884	CbGpPWpGaD
Crizotinib—LCK—Immune System—MB21D1—conduct disorder	0.000413	0.000874	CbGpPWpGaD
Crizotinib—EPHA3—Developmental Biology—EP300—conduct disorder	0.000413	0.000872	CbGpPWpGaD
Crizotinib—ABL2—Developmental Biology—EP300—conduct disorder	0.000413	0.000872	CbGpPWpGaD
Crizotinib—EPHA5—Developmental Biology—EP300—conduct disorder	0.000413	0.000872	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CGA—conduct disorder	0.000411	0.000869	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—HTR2A—conduct disorder	0.000409	0.000865	CbGpPWpGaD
Crizotinib—ABL1—Factors involved in megakaryocyte development and platelet production—EP300—conduct disorder	0.000409	0.000864	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CGA—conduct disorder	0.000398	0.000843	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—CGA—conduct disorder	0.000398	0.000842	CbGpPWpGaD
Crizotinib—EPHA8—Developmental Biology—EP300—conduct disorder	0.000398	0.000842	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—WASF1—conduct disorder	0.000396	0.000838	CbGpPWpGaD
Crizotinib—EPHB4—Developmental Biology—EP300—conduct disorder	0.000394	0.000832	CbGpPWpGaD
Crizotinib—EPHA4—Developmental Biology—EP300—conduct disorder	0.000394	0.000832	CbGpPWpGaD
Crizotinib—LIMK2—Developmental Biology—EP300—conduct disorder	0.000394	0.000832	CbGpPWpGaD
Crizotinib—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.000392	0.00083	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—WASF1—conduct disorder	0.000392	0.000828	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—WASF1—conduct disorder	0.000388	0.000821	CbGpPWpGaD
Crizotinib—LIMK1—Developmental Biology—EP300—conduct disorder	0.000385	0.000814	CbGpPWpGaD
Crizotinib—TYK2—Immune System—WASF1—conduct disorder	0.000385	0.000814	CbGpPWpGaD
Crizotinib—JAK2—Factors involved in megakaryocyte development and platelet production—EP300—conduct disorder	0.000384	0.000813	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—DRD4—conduct disorder	0.000379	0.000801	CbGpPWpGaD
Crizotinib—ABL1—Integrated Breast Cancer Pathway—EP300—conduct disorder	0.000376	0.000795	CbGpPWpGaD
Crizotinib—IKBKE—Innate Immune System—EP300—conduct disorder	0.000374	0.000791	CbGpPWpGaD
Crizotinib—AURKA—Cell Cycle, Mitotic—EP300—conduct disorder	0.000373	0.000788	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—DRD4—conduct disorder	0.000371	0.000784	CbGpPWpGaD
Crizotinib—LYN—Immune System—POLR3A—conduct disorder	0.00037	0.000783	CbGpPWpGaD
Crizotinib—TEK—Hemostasis—EP300—conduct disorder	0.00037	0.000783	CbGpPWpGaD
Crizotinib—EPHB6—Developmental Biology—EP300—conduct disorder	0.00037	0.000782	CbGpPWpGaD
Crizotinib—ABL1—Immune System—POLR3A—conduct disorder	0.000369	0.000779	CbGpPWpGaD
Crizotinib—SRC—Immune System—MB21D1—conduct disorder	0.000366	0.000774	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—HTR2A—conduct disorder	0.00036	0.000762	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—HTR2A—conduct disorder	0.00036	0.000762	CbGpPWpGaD
Crizotinib—PLK4—Cell Cycle, Mitotic—EP300—conduct disorder	0.000357	0.000756	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—WASF1—conduct disorder	0.000349	0.000738	CbGpPWpGaD
Crizotinib—EPHA6—Developmental Biology—EP300—conduct disorder	0.000348	0.000736	CbGpPWpGaD
Crizotinib—JAK2—Immune System—POLR3A—conduct disorder	0.000346	0.000733	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—WASF1—conduct disorder	0.000344	0.000728	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CGA—conduct disorder	0.000342	0.000723	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—HTR2A—conduct disorder	0.000342	0.000723	CbGpPWpGaD
Crizotinib—MAPK7—Innate Immune System—EP300—conduct disorder	0.00034	0.000719	CbGpPWpGaD
Crizotinib—LIMK1—Innate Immune System—EP300—conduct disorder	0.00034	0.000719	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CGA—conduct disorder	0.000337	0.000713	CbGpPWpGaD
Crizotinib—AURKA—Cell Cycle—EP300—conduct disorder	0.000333	0.000705	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—HTR2A—conduct disorder	0.000333	0.000704	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—WASF1—conduct disorder	0.000329	0.000696	CbGpPWpGaD
Crizotinib—EPHA2—Developmental Biology—EP300—conduct disorder	0.000321	0.000678	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CGA—conduct disorder	0.00032	0.000676	CbGpPWpGaD
Crizotinib—PLK4—Cell Cycle—EP300—conduct disorder	0.000319	0.000676	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—WASF1—conduct disorder	0.000319	0.000675	CbGpPWpGaD
Crizotinib—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.000314	0.000665	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—HTR2A—conduct disorder	0.000313	0.000661	CbGpPWpGaD
Crizotinib—LYN—Immune System—WASF1—conduct disorder	0.000312	0.000659	CbGpPWpGaD
Crizotinib—ABL1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000312	0.000659	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CGA—conduct disorder	0.00031	0.000656	CbGpPWpGaD
Crizotinib—ABL1—Immune System—WASF1—conduct disorder	0.00031	0.000656	CbGpPWpGaD
Crizotinib—SRC—TGF-beta Signaling Pathway—EP300—conduct disorder	0.000305	0.000645	CbGpPWpGaD
Crizotinib—LCK—Immune System—POLR3A—conduct disorder	0.000303	0.000642	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—HTR2A—conduct disorder	0.000302	0.000639	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—DRD4—conduct disorder	0.000294	0.000622	CbGpPWpGaD
Crizotinib—JAK2—Immune System—WASF1—conduct disorder	0.000292	0.000617	CbGpPWpGaD
Crizotinib—TXK—Immune System—EP300—conduct disorder	0.000287	0.000608	CbGpPWpGaD
Crizotinib—JAK3—Hemostasis—EP300—conduct disorder	0.000279	0.00059	CbGpPWpGaD
Crizotinib—TBK1—Innate Immune System—EP300—conduct disorder	0.000278	0.000588	CbGpPWpGaD
Crizotinib—CDK7—Cell Cycle, Mitotic—EP300—conduct disorder	0.000275	0.000582	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—WASF1—conduct disorder	0.000274	0.000579	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—DRD4—conduct disorder	0.000274	0.000579	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—HTR2A—conduct disorder	0.000273	0.000578	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—WASF1—conduct disorder	0.00027	0.000571	CbGpPWpGaD
Crizotinib—SRC—Immune System—POLR3A—conduct disorder	0.000269	0.000568	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—EP300—conduct disorder	0.000268	0.000567	CbGpPWpGaD
Crizotinib—JAK2—Chromatin modifying enzymes—EP300—conduct disorder	0.000264	0.000559	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.000258	0.000547	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—WASF1—conduct disorder	0.000256	0.000542	CbGpPWpGaD
Crizotinib—LCK—Immune System—WASF1—conduct disorder	0.000255	0.00054	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CGA—conduct disorder	0.000251	0.000532	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—WASF1—conduct disorder	0.000249	0.000526	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—HTR2A—conduct disorder	0.000247	0.000522	CbGpPWpGaD
Crizotinib—CDK7—Cell Cycle—EP300—conduct disorder	0.000246	0.00052	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—DRD4—conduct disorder	0.000246	0.000519	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—DRD4—conduct disorder	0.000244	0.000516	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—HTR2A—conduct disorder	0.000242	0.000511	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—DRD4—conduct disorder	0.00024	0.000509	CbGpPWpGaD
Crizotinib—FGR—Hemostasis—EP300—conduct disorder	0.000239	0.000504	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CGA—conduct disorder	0.000235	0.000498	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—DRD4—conduct disorder	0.00023	0.000487	CbGpPWpGaD
Crizotinib—PRKD1—Metabolism—EP300—conduct disorder	0.000228	0.000483	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—EP300—conduct disorder	0.000228	0.000482	CbGpPWpGaD
Crizotinib—SRC—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000227	0.00048	CbGpPWpGaD
Crizotinib—SRC—Immune System—WASF1—conduct disorder	0.000226	0.000478	CbGpPWpGaD
Crizotinib—RIPK2—Innate Immune System—EP300—conduct disorder	0.000224	0.000474	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—DRD4—conduct disorder	0.000223	0.000472	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—DRD4—conduct disorder	0.000223	0.000472	CbGpPWpGaD
Crizotinib—IKBKE—Immune System—EP300—conduct disorder	0.000218	0.00046	CbGpPWpGaD
Crizotinib—FGR—Innate Immune System—EP300—conduct disorder	0.000215	0.000454	CbGpPWpGaD
Crizotinib—CYP3A4—Biological oxidations—COMT—conduct disorder	0.00021	0.000444	CbGpPWpGaD
Crizotinib—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.000208	0.000441	CbGpPWpGaD
Crizotinib—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.000207	0.000438	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CGA—conduct disorder	0.000206	0.000436	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—WASF1—conduct disorder	0.000201	0.000426	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—EP300—conduct disorder	0.000199	0.000421	CbGpPWpGaD
Crizotinib—MAPK7—Immune System—EP300—conduct disorder	0.000198	0.000419	CbGpPWpGaD
Crizotinib—LIMK1—Immune System—EP300—conduct disorder	0.000198	0.000419	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—EP300—conduct disorder	0.000196	0.000415	CbGpPWpGaD
Crizotinib—PTK2—Hemostasis—EP300—conduct disorder	0.000195	0.000413	CbGpPWpGaD
Crizotinib—YES1—Hemostasis—EP300—conduct disorder	0.000193	0.000407	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HTR2A—conduct disorder	0.000192	0.000406	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—DRD4—conduct disorder	0.000191	0.000405	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—EP300—conduct disorder	0.000191	0.000404	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—EP300—conduct disorder	0.000191	0.000404	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—DRD4—conduct disorder	0.000189	0.000399	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—WASF1—conduct disorder	0.000189	0.000399	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CGA—conduct disorder	0.000182	0.000386	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—EP300—conduct disorder	0.000181	0.000383	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—EP300—conduct disorder	0.000181	0.000382	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—DRD4—conduct disorder	0.000179	0.000379	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HTR2A—conduct disorder	0.000179	0.000378	CbGpPWpGaD
Crizotinib—PTK2—Innate Immune System—EP300—conduct disorder	0.000176	0.000372	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—DRD4—conduct disorder	0.000174	0.000368	CbGpPWpGaD
Crizotinib—YES1—Innate Immune System—EP300—conduct disorder	0.000173	0.000367	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CGA—conduct disorder	0.000171	0.000362	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—EP300—conduct disorder	0.000166	0.00035	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—WASF1—conduct disorder	0.000165	0.000349	CbGpPWpGaD
Crizotinib—IRAK1—Innate Immune System—EP300—conduct disorder	0.000164	0.000348	CbGpPWpGaD
Crizotinib—TBK1—Immune System—EP300—conduct disorder	0.000162	0.000342	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—HTR2A—conduct disorder	0.00016	0.000339	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—EP300—conduct disorder	0.00016	0.000337	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HTR2A—conduct disorder	0.000159	0.000337	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HTR2A—conduct disorder	0.000157	0.000332	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—EP300—conduct disorder	0.000155	0.000328	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HTR2A—conduct disorder	0.00015	0.000318	CbGpPWpGaD
Crizotinib—JAK3—Immune System—EP300—conduct disorder	0.000146	0.00031	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—EP300—conduct disorder	0.000146	0.000309	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—WASF1—conduct disorder	0.000146	0.000309	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—EP300—conduct disorder	0.000146	0.000308	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HTR2A—conduct disorder	0.000146	0.000308	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HTR2A—conduct disorder	0.000146	0.000308	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—EP300—conduct disorder	0.000145	0.000306	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—EP300—conduct disorder	0.000144	0.000304	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—EP300—conduct disorder	0.000143	0.000302	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD4—conduct disorder	0.000141	0.000298	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—EP300—conduct disorder	0.000137	0.00029	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.000134	0.000284	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—EP300—conduct disorder	0.000134	0.000284	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD4—conduct disorder	0.000132	0.000279	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—EP300—conduct disorder	0.000131	0.000277	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—EP300—conduct disorder	0.00013	0.000276	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—EP300—conduct disorder	0.000129	0.000273	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CGA—conduct disorder	0.000129	0.000273	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—EP300—conduct disorder	0.000129	0.000272	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—EP300—conduct disorder	0.000129	0.000272	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—EP300—conduct disorder	0.000128	0.000271	CbGpPWpGaD
Crizotinib—CDK7—Disease—EP300—conduct disorder	0.000126	0.000267	CbGpPWpGaD
Crizotinib—BLK—Immune System—EP300—conduct disorder	0.000125	0.000265	CbGpPWpGaD
Crizotinib—FGR—Immune System—EP300—conduct disorder	0.000125	0.000264	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HTR2A—conduct disorder	0.000125	0.000264	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HTR2A—conduct disorder	0.000123	0.000261	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—EP300—conduct disorder	0.000121	0.000256	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—EP300—conduct disorder	0.000118	0.000249	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HTR2A—conduct disorder	0.000117	0.000247	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD4—conduct disorder	0.000115	0.000244	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HTR2A—conduct disorder	0.000113	0.00024	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—EP300—conduct disorder	0.000106	0.000225	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—EP300—conduct disorder	0.000106	0.000224	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—EP300—conduct disorder	0.000104	0.00022	CbGpPWpGaD
Crizotinib—PTK2—Immune System—EP300—conduct disorder	0.000102	0.000216	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD4—conduct disorder	0.000102	0.000216	CbGpPWpGaD
Crizotinib—YES1—Immune System—EP300—conduct disorder	0.000101	0.000213	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—EP300—conduct disorder	9.57e-05	0.000202	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—EP300—conduct disorder	9.46e-05	0.0002	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—EP300—conduct disorder	9.38e-05	0.000198	CbGpPWpGaD
Crizotinib—TYK2—Immune System—EP300—conduct disorder	9.3e-05	0.000197	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HTR2A—conduct disorder	9.19e-05	0.000194	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HTR2A—conduct disorder	8.6e-05	0.000182	CbGpPWpGaD
Crizotinib—TYK2—Disease—EP300—conduct disorder	8.58e-05	0.000181	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—EP300—conduct disorder	8.43e-05	0.000178	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—EP300—conduct disorder	8.31e-05	0.000176	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—EP300—conduct disorder	7.96e-05	0.000168	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CGA—conduct disorder	7.95e-05	0.000168	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—COMT—conduct disorder	7.72e-05	0.000163	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—EP300—conduct disorder	7.71e-05	0.000163	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—MAOA—conduct disorder	7.67e-05	0.000162	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HTR2A—conduct disorder	7.53e-05	0.000159	CbGpPWpGaD
Crizotinib—LYN—Immune System—EP300—conduct disorder	7.53e-05	0.000159	CbGpPWpGaD
Crizotinib—ABL1—Immune System—EP300—conduct disorder	7.49e-05	0.000158	CbGpPWpGaD
Crizotinib—JAK2—Immune System—EP300—conduct disorder	7.04e-05	0.000149	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HTR2A—conduct disorder	6.67e-05	0.000141	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—EP300—conduct disorder	6.62e-05	0.00014	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—EP300—conduct disorder	6.53e-05	0.000138	CbGpPWpGaD
Crizotinib—JAK2—Disease—EP300—conduct disorder	6.5e-05	0.000138	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—EP300—conduct disorder	6.19e-05	0.000131	CbGpPWpGaD
Crizotinib—LCK—Immune System—EP300—conduct disorder	6.17e-05	0.00013	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—EP300—conduct disorder	6.01e-05	0.000127	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—COMT—conduct disorder	5.83e-05	0.000123	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—MAOA—conduct disorder	5.79e-05	0.000122	CbGpPWpGaD
Crizotinib—LCK—Disease—EP300—conduct disorder	5.7e-05	0.00012	CbGpPWpGaD
Crizotinib—SRC—Immune System—EP300—conduct disorder	5.46e-05	0.000116	CbGpPWpGaD
Crizotinib—SRC—Disease—EP300—conduct disorder	5.04e-05	0.000107	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—EP300—conduct disorder	4.87e-05	0.000103	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—EP300—conduct disorder	4.55e-05	9.63e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—EP300—conduct disorder	3.99e-05	8.44e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—COMT—conduct disorder	3.59e-05	7.59e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—MAOA—conduct disorder	3.56e-05	7.54e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—EP300—conduct disorder	3.53e-05	7.47e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—EP300—conduct disorder	3.31e-05	7e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—EP300—conduct disorder	2.5e-05	5.28e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—EP300—conduct disorder	1.54e-05	3.26e-05	CbGpPWpGaD
